ALLOGENE THERAPEUTICS to Present at 41st Annual J.P. Morgan Healthcare Conference in 2023
January 8, 2023
Trending News 🌥️
Allogene Therapeutics ($NASDAQ:ALLO) is a clinical-stage biotechnology company that focuses on the development of allogeneic chimeric antigen receptor (CAR) T cell therapy for the treatment of hematologic and solid tumors. The company has developed an allogenic CAR T platform technology, which is designed to reduce the cost and time associated with autologous CAR T therapy. The platform also eliminates the need for patient-specific cells and enables the manufacture of off-the-shelf CAR T products. Allogene Therapeutics is set to be a part of the 41st Annual J.P. Morgan Healthcare Conference on January 4, 2023. This conference is one of the world’s largest and most influential healthcare investment symposiums, and includes presentations from leading healthcare companies and organizations. During the conference, Allogene will provide an update about its ongoing clinical studies, as well as its plans for commercializing its CAR T cell therapy products.
Furthermore, it will provide an overview of its pipeline and discuss potential strategic collaborations with other companies. This is an important milestone for Allogene Therapeutics and it demonstrates the company’s commitment to developing innovative therapies. By presenting at the J.P. Morgan Healthcare Conference, Allogene is able to share its progress with investors and other healthcare industry professionals. It is a great opportunity for the company to showcase its technology and gain exposure in the healthcare industry. The conference will also provide Allogene with a platform for engaging with potential partners and exploring new opportunities for collaboration.
Price History
On Wednesday, Allogene Therapeutics stock opened at $5.8 and closed at $5.8, up by 0.7% from prior closing price of 5.8. The J.P. Morgan Healthcare Conference has long been known to be a key event in the healthcare industry, bringing together the most influential investors, analysts and executives from around the world. This year Allogene Therapeutics will have the opportunity to present their company and share their plans for the future. At this event, they will be able to demonstrate how their novel treatments are transforming the world of cancer therapy.
The 41st Annual J.P. Morgan Healthcare Conference promises to be an exciting event for Allogene Therapeutics, as they hope to build on their current success and bring their innovative treatments to more patients in need. As the company continues to grow and expand its reach, it is expected that Allogene Therapeutics stock prices will only continue to rise. With a strong presence at the conference, they will be able to demonstrate their commitment to transforming the world of cancer therapy and create even more value for their investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Allogene Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.25 | -312.65 | -126580.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Allogene Therapeutics. More…
| Operations | Investing | Financing |
| -203.86 | 85.81 | 3.23 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Allogene Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 887.57 | 147.61 | 5.14 |
Key Ratios Snapshot
Some of the financial key ratios for Allogene Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -126707.7% |
| FCF Margin | ROE | ROA |
| -84248.6% | -25.4% | -22.0% |
VI Analysis
Company fundamentals are important for investors to assess the long term potential of a business. By utilizing the VI App, investors can gain a quick understanding of the company’s fundamentals. According to the VI Risk Rating, Allogene Therapeutics is considered a medium risk investment, with considerations taken from both the financial and business aspects of the company. The VI App has detected three risk warnings in the balance sheet, cash flow statement, and financial journal of Allogene Therapeutics. These warnings are meant to alert investors that further research may be necessary to make an informed decision about investing in this company. It is important for investors to understand the risks associated with any investment and the VI App provides an easy-to-understand assessment of those risks. Furthermore, the VI App allows investors to view comparable investments and their respective risk ratings, giving investors a better understanding of the company’s position and potential investment opportunities. This allows investors to make better decisions regarding their investments. Overall, the VI App provides a useful tool for investors to assess the risk of investing in Allogene Therapeutics. By providing a simple assessment of the company’s financial and business fundamentals, investors can make more informed decisions about their investments. For those wishing to further investigate Allogene Therapeutics, they can register on the VI App to view the detected risk warnings and compare other investments. More…
VI Peers
Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company, engaged in the development of allogeneic CAR T cell therapies for the treatment of cancer. Allogene Therapeutics Inc’s competitors are Arvinas Inc, Nascent Biotech Inc, JW (Cayman) Therapeutics Co Ltd.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing proteolysis-targeting chimeras (PROTACs) to degrade and control proteins that drive disease. Arvinas has a market cap of 2.29B as of 2022 and a Return on Equity of -32.37%. The company’s lead product candidate, ARV-110, is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas is also developing ARV-471 for the treatment of HER2-positive breast cancer and ARV-825 for the treatment of urothelial cancer.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a clinical-stage biopharmaceutical company with a focus on developing monoclonal antibodies to treat various cancers. The company’s market cap is 26.93M as of 2022 and its ROE is 55.87%. Nascent Biotech Inc is a relatively small company, but it has shown impressive growth potential. The company’s focus on developing monoclonal antibodies to treat cancer is a promising area of research that could lead to breakthrough treatments for this devastating disease.
– JW (Cayman) Therapeutics Co Ltd ($SEHK:02126)
JW (Cayman) Therapeutics Co Ltd is a clinical stage biopharmaceutical company focused on developing and commercializing novel cancer immunotherapies. The company’s lead product candidate, JTX-2011, is a first-in-class, off-the-shelf, multi-antigen targeted T cell therapy being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. JW (Cayman) Therapeutics Co Ltd has a market cap of 1.32B as of 2022, a Return on Equity of -19.61%.
Summary
Allogene Therapeutics is an immuno-oncology company focused on developing allogeneic CAR T therapies for cancer. The company is presenting at the 41st Annual J.P. Morgan Healthcare Conference in 2023, providing investors with an opportunity to gain insight into their potential future performance. Investors should consider Allogene Therapeutics’ current and future financials, market trends, competitive landscape, and potential risks to determine the best investment decision. Allogene Therapeutics’ pipeline of products and clinical trials will also be important to consider, as well as any potential partnerships or collaborations that may have been formed.
Additionally, investors should carefully evaluate Allogene Therapeutics’ management team and any potential strategic plans they may have in place.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
